NCT02564575View on ClinicalTrials.gov

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Hemorrhagic Fever, Ebola
Interventions
BIOLOGICAL

HPIV3-EbovZ GP Vaccine

Administered intranasally by a VaxINator device

Trial Locations (1)

Unknown

Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health (JHBSPH), Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02564575 - Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults | Biotech Hunter | Biotech Hunter